Neijenhuis Ralph Ml, Regeer Madelien V, Walker Niki L, Mertens Bart Ja, Hunter Amanda, Kiès Philippine, Swan Lorna, Vliegen Hubert W, MacDonald Simon T, Zemrak Filip, Zaidi Ali N, Cedars Ari M, Jongbloed Monique Rm, Jukema J Wouter, Veldtman Gruschen R, Egorova Anastasia D
Center for Congenital Heart Disease Amsterdam-Leiden (CAHAL), Leiden University Medical Center, Leiden, The Netherlands.
Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
Open Heart. 2025 Jul 21;12(2):e003445. doi: 10.1136/openhrt-2025-003445.
Systemic right ventricle (sRV) patients are at an increased risk of developing heart failure. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) could be a valuable treatment option. This study investigated the changes in ventricular function in sRV failure patients in the first year after starting SGLT2i.
Adult sRV patients from the international, real-world ACHIEVE-SGLT2i registry were included if they had a clinical diagnosis of sRV failure, a transthoracic echocardiogram before starting SGLT2i, and at least one in the first year after starting available for analysis. The primary outcomes were changes in sRV global longitudinal strain (GLS) and fractional area change (FAC). Longitudinal changes were evaluated using linear mixed models.
Thirty-nine sRV failure patients (46±9.3 years old, 41% female) were included. Twenty-five (64%) had transposition of the great arteries after an atrial switch procedure and 14 (36%) had congenitally corrected transposition. sRV GLS improved significantly in the first 50 days (-1.4%-point per month, p<0.001) and stabilised afterwards (<0.1%-point per month, p=0.520). Though age had a significant overall negative effect on sRV GLS (0.1%-point per year of age, p=0.049), it did not influence the longitudinal changes after starting SGLT2i. sRV FAC also improved in the first 50 days (3.2%-point per month, p=0.002), after which sRV FAC deteriorated in patients with subpulmonary left ventricular pacing (-0.9%-point per month, p=0.012) while it stabilised in patients without pacing (0.1%-point per month, p=0.573). In the first 50 days, tricuspid annular plane systolic excursion also improved significantly in all patients (1.2 mm per month, p=0.006), and stabilised afterwards (p=0.721).
SGLT2i therapy is associated with improvements in systolic ventricular function in sRV failure patients. Despite early improvement in sRV FAC, there was a negative longer term correlation with subpulmonary left ventricular pacing, potentially reflecting adverse effects of subpulmonary ventricular pacing on sRV function.
系统性右心室(sRV)患者发生心力衰竭的风险增加。钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)可能是一种有价值的治疗选择。本研究调查了sRV衰竭患者开始使用SGLT2i后第一年心室功能的变化。
纳入国际真实世界ACHIEVE-SGLT2i注册研究中的成年sRV患者,这些患者需有sRV衰竭的临床诊断,在开始使用SGLT2i前进行过经胸超声心动图检查,且在开始使用后的第一年至少有一次可用于分析的数据。主要结局指标为sRV整体纵向应变(GLS)和面积变化分数(FAC)的变化。使用线性混合模型评估纵向变化。
纳入39例sRV衰竭患者(46±9.3岁,41%为女性)。25例(64%)在心房调转手术后发生大动脉转位,14例(36%)为先天性矫正型大动脉转位。sRV GLS在开始后的前50天显著改善(每月-1.4个百分点,p<0.001),之后趋于稳定(每月<0.1个百分点,p=0.520)。尽管年龄对sRV GLS有显著的总体负面影响(每年0.1个百分点,p=0.049),但它并不影响开始使用SGLT2i后的纵向变化。sRV FAC在开始后的前50天也有所改善(每月3.2个百分点,p=0.002),之后,肺动脉下左心室起搏患者的sRV FAC恶化(每月-0.9个百分点,p=0.012),而未起搏患者的sRV FAC则趋于稳定(每月0.1个百分点,p=0.573)。在开始后的前50天,所有患者的三尖瓣环平面收缩期位移也显著改善(每月1.2毫米,p=0.006),之后趋于稳定(p=0.721)。
SGLT2i治疗与sRV衰竭患者的心室收缩功能改善相关。尽管sRV FAC早期有所改善,但与肺动脉下左心室起搏存在长期负相关,这可能反映了肺动脉下心室起搏对sRV功能的不利影响。